New stroke drug BB-031 enters Mid-Stage trial
Disease control
Recruiting now
This study tests a new drug called BB-031 in people who have had a stroke caused by a blood clot. The goal is to see if the drug is safe and how the body handles it. About 228 participants will receive either the drug or a placebo within 24 hours of their stroke and be monitored …
Phase: PHASE2 • Sponsor: Basking Biosciences, Inc. • Aim: Disease control
Last updated May 17, 2026 10:28 UTC